美股异动丨Regenxbio盘前暴跌32%

Group 1 - The core point of the article is that Regenxbio's stock price plummeted by 32% in pre-market trading following the FDA's decision to impose a clinical hold on its gene therapy trial [1] Group 2 - The FDA's action indicates potential regulatory challenges for the company, which may impact its future development and commercialization plans [1] - The significant drop in stock price reflects investor concerns regarding the viability of Regenxbio's gene therapy program [1] - The clinical hold could delay the timeline for potential product launches, affecting the company's revenue projections [1]